Acumen Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Acumen Pharmaceuticals Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation: Delaware
Headquarters city: Newton
Headquarters state / province: Massachusetts
Headquarters country: United States
Fiscal year end: December
Ticker symbol: ABOS
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001576885
EIN: 36-4108129

Board of directors

Follow this board

Daniel Joseph OConnell · Director · Chief Executive Officer
Since 2023
Derrell Porter · Director
Since 2023
George Golumbeski · Director
Since 2025
Jeffrey L. Ives · Director
Since 2023
John A. Stalfort III · Director
Since 2023
Kimberlee C. Drapkin · Director
Since 2023
Laura Stoppel · Director
Since 2023
Nathan B. Fountain · Director
Since 2023
Peter Kolchinsky · Director Overboarded
Since 2023
Rajeev M. Shah · Director Overboarded
Since 2023

Chief executives

Daniel Joseph OConnell · President and CEO

Dates unknown

Director election results

Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 30 other boards. 30 are in the same sector.

Shared director Other board Same sector +14 more in the list below

Artiva Biotherapeutics Inc. Same sector
via Laura Stoppel, Peter Kolchinsky and Rajeev M. Shah
Climb Bio Inc. Same sector
via Kimberlee C. Drapkin, Peter Kolchinsky and Rajeev M. Shah
LENZ Therapeutics Inc. Same sector
via Kimberlee C. Drapkin, Peter Kolchinsky and Rajeev M. Shah
ARS Pharmaceuticals Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Acrivon Therapeutics Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Bambusa Therapeutics Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Bicara Therapeutics Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Black Diamond Therapeutics Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Evommune Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Freenome Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Hemab Therapeutics Holdings Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Jade Biosciences Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Janux Therapeutics Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Mineralys Therapeutics Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Nkarta Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Parabilis Medicines Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
PepGen Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Septerna Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Sionna Therapeutics Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Solid Biosciences Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
SpyGlass Pharma Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Tyra Biosciences Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Vor Biopharma Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Wave Life Sciences Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Werewolf Therapeutics Inc. Same sector
via Peter Kolchinsky and Rajeev M. Shah
Passage Bio Inc. Same sector
via Derrell Porter
Shattuck Labs Inc. Same sector
via George Golumbeski
Taysha Gene Therapies Inc. Same sector
via John A. Stalfort III
Tvardi Therapeutics Inc. Same sector
via Jeffrey L. Ives
Verrica Pharmaceuticals Inc. Same sector
via John A. Stalfort III

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $625,712; 48 sales by 9 insiders

Date	Insider	Transaction	Shares	Price	Value
Jun 17, 2026	Derrell Porter Director	Option exercise	+13,040	$1.07	$13,953
Jun 17, 2026	Derrell Porter Director	Open-market sale	−13,040	$2.33	$30,383
Jun 16, 2026	Derrell Porter Director	Open-market sale	−12,800	$2.33	$29,824
Jun 15, 2026	Derrell Porter Director	Option exercise	+6,460	$1.07	$6,912
Jun 15, 2026	Derrell Porter Director	Open-market sale	−6,460	$2.35	$15,181
Jun 9, 2026	Nathan B. Fountain Director	Open-market sale	−6,400	$2.23	$14,272
Jun 3, 2026	RA Capital Nexus Fund II, L.P. Director	Grant or award	+35,500	—	—
Jun 3, 2026	Nathan B. Fountain Director	Grant or award	+35,500	—	—
Jun 3, 2026	Kimberlee C. Drapkin Director	Grant or award	+35,500	—	—
Jun 3, 2026	John A. Stalfort III Director	Grant or award	+35,500	—	—
Jun 3, 2026	Derrell Porter Director	Grant or award	+35,500	—	—
Jun 3, 2026	Jeffrey L. Ives Director	Grant or award	+35,500	—	—
Jun 3, 2026	George Golumbeski Director	Grant or award	+35,500	—	—
Jun 3, 2026	Laura Stoppel Director	Grant or award	+35,500	—	—
Mar 16, 2026	Rajeev M. Shah Director, 10% owner	Grant or award	+6,060,606	$3.30	$20,000,000

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Acumen Pharmaceuticals Inc.

Who is the CEO of Acumen Pharmaceuticals Inc.?

Daniel Joseph OConnell is Acumen Pharmaceuticals Inc.'s President and CEO.

How many directors are on Acumen Pharmaceuticals Inc.'s board?

Acumen Pharmaceuticals Inc.'s board has 10 directors: Daniel Joseph OConnell, Derrell Porter, George Golumbeski, Jeffrey L. Ives, John A. Stalfort III, Kimberlee C. Drapkin, Laura Stoppel, Nathan B. Fountain, Peter Kolchinsky and Rajeev M. Shah.

Are Acumen Pharmaceuticals Inc. insiders buying or selling shares?

Over the last 12 months, Acumen Pharmaceuticals Inc. insiders made no open-market purchases and sold $625,712 of shares in 48 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Acumen Pharmaceuticals Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="acumen-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.